– Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia –

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company’s leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto’s COO, Mike will be responsible for new product planning, portfolio strategy, and cross-functional leadership to maximize the impact of the Company’s clinical-stage programs and biomarker platform.

“Mike has dedicated his career to leading the product life cycle for companies in CNS and psychiatry, from early-stage planning and portfolio strategy through launch and brand management,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto. “His expertise will be instrumental as we advance into late-stage clinical development and execute on our mission to bring targeted treatments to those in need. At Alto we aim to develop each of our programs based on sound scientific, strategic, and commercial considerations; we believe adding Mike to the team at this juncture will further our ability to do this across our broad pipeline.”

Prior to joining Alto, Mr. Hanley served as chief commercial officer and chief business officer at Aeglea BioTherapeutics. Previously, he was the general manager at Horizon Therapeutics and head of U.S. sales for Lundbeck’s psychiatry business unit, where he was responsible for managing TRINTELLIX (vortioxetine), ABILIFY MAINTENA (aripiprazole), and preparing for the launch of REXULTI (brexpiprazole). Throughout his career, Mr. Hanley has worked in, and held leadership roles across, various therapeutic areas including major depressive disorder, schizophrenia, sleep disorders, epilepsy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Mr. Hanley received a Bachelor of Business Administration in Marketing from the University of Notre Dame and a Master of Business Administration from the Kellogg School of Management at Northwestern University.

“Alto is a mission-driven company dedicated to transforming mental health treatments, and I am eager to join a team that has a strong scientific acumen and proven track record in the field,” added Mr. Hanley. “I look forward to leveraging my knowledge in CNS and operational experience to maximize the potential of our precision psychiatry platform and help advance our pipeline toward a number of important near-term clinical data readouts.”

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521805369/en/